Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes

Julia Montoro, Laura Gallur, Brayan Merchán, Antonieta Molero, Elisa Roldán, Ferrán Martínez-Valle, Guillermo Villacampa, Mayda Navarrete, Margarita Ortega, Josep Castellví, Silvia Saumell, Sabela Bobillo, Francesc Bosch, David Valcárcel

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


© 2018, Springer-Verlag GmbH Germany, part of Springer Nature. The coexistence of autoimmune disorders (AD) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) has been widely recognized, although with distinct results regarding their prevalence and impact on the outcomes of the underlying hematological process. This study was aimed to analyze the prevalence, clinical characteristics, and outcomes of MDS with AD in a series of 142 patients diagnosed with MDS and CMML. AD was ascertained by both the presence of clinical symptoms or compatible serological tests. In total, 48% patients were diagnosed as having AD, being hypothyroidism the most commonly reported clinical AD (8%) and antinuclear antibodies the most frequent serological parameter identified (23.2%). The presence of AD was associated with female gender, lower hemoglobin levels, and higher IPSS-R. Overall survival for patients with AD was inferior to those with no AD (69 vs. 88% at 30 months; HR 2.75, P = 0.008). Notably, clinical but not isolated immune serological parameters had an impact on the outcomes of patients with AD. Finally, in a multivariate analysis, the presence of AD (HR 2.26) along with disease risk categories (very low and low vs. intermediate, high, and very high IPSS-R; HR 4.62) retained their independent prognostic value (P < 0.001). In conclusion, AD are prevalent in MDS and CMML patients and have prognostic implications, especially in lower-risk MDS patients.
Original languageEnglish
Pages (from-to)1349-1356
JournalAnnals of Hematology
Issue number8
Publication statusPublished - 1 Aug 2018


  • Autoimmune disorders
  • Chronic myelomonocytic leukemia
  • Immune dysregulation
  • Myelodysplastic syndrome


Dive into the research topics of 'Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes'. Together they form a unique fingerprint.

Cite this